Top

Published in:

01-06-2011 | Invited Commentary

Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?

Author: Kathleen I. Pritchard

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Excerpt

The very interesting article published in this issue of breast cancer research and treatment uses long term follow up of the International Breast Cancer Study Group (IBCSG) Trials III and IV to make several important points with regard to the natural history, biology and treatment of breast cancer. …

Bonetti M, Gelber RD (2000) A graphical method to assess treatment—covariate interactions using the Cox model on subsets of the data. Stat Med 19:2595–2609. doi:10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M PubMedCrossRef

Bonetti M, Gelber RD (2004) Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5:465–481. doi:10.1093/biostatistics/kxh002 PubMedCrossRef

Regan MM, Gelber RD, For the International Breast Cancer Study Group (2006) Predicting response to systemic treatments; learning from the past to plan for the future. Breast 14:582–593. doi:10.1016/j.breast.2005.08.021 CrossRef

Regan MM, Gelber RD (2007) Using clinical trial data to tailor adjuvant treatments for individual patients. Breast 16:98–104. doi:10.1016/j.breast.2007.07.016 CrossRef

Berry DA, Cirrincione C, Henderson IC et al (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658–1667. doi:10.1001/jama.295.14.1658 PubMedCrossRef

Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983. doi:10.1200/JCO.2003.02.063 PubMedCrossRef

Citron M, Berry D, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/cancer and leukemia group B Trial 9741. J Clin Oncol 21:1–9. doi:10.1200/JCO.2003.09.081 CrossRef

Title: Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?
Author: Kathleen I. Pritchard
Publication date: 01-06-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0325-1

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2011

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial

Further studies based on better design are needed to explore the association of NPAS2 gene polymorphisms with breast cancer

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

Three-dimensional collagen represses cyclin E1 via β1 integrin in invasive breast cancer cells